• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用可穿戴心脏除颤器的女性围产期与非围产期心肌病的特征和结局。

Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator.

机构信息

Christiana Care Health System, Newark, DE 19718, USA.

出版信息

J Card Fail. 2012 Jan;18(1):21-7. doi: 10.1016/j.cardfail.2011.09.004. Epub 2011 Oct 19.

DOI:10.1016/j.cardfail.2011.09.004
PMID:22196837
Abstract

BACKGROUND

Peripartum cardiomyopathy (PPCM) mortality rates vary between 2% and 56%, with half occurring ≤12 weeks'; postpartum. Although risk factors for PPCM have been identified, predicting sudden cardiac death among PPCM patients remains difficult. This study describes the characteristics and outcomes of PPCM patients and controls referred for a wearable cardioverter defibrillator (WCD).

METHODS AND RESULTS

Deidentified WCD medical orders between 2003 and 2009 and death index searches were used to characterize women (ages 17-43) with PPCM (n = 107) or matched nonpregnant women with nonischemic dilated cardiomyopathy (NIDCM; n = 159). Demographics were similar. WCD use averaged 124 ± 123 days and 96 ± 83 days among PPCM and NIDCM patients, respectively. No PPCM patients received an appropriate shock for ventricular tachycardia/ventricular fibrillation; 1 NIDCM patient received 2 successful shocks. No PPCM patient died during WCD use versus 11 concurrent NIDCM deaths. After WCD use, 3 PPCM and 13 NIDCM patients died, respectively.

CONCLUSIONS

The mortality rate of 2.8% (over 3.0 ± 1.2 years) in PPCM patients is low compared to published data. The role of WCD therapy among PPCM patients deserves further study.

摘要

背景

围产期心肌病(PPCM)的死亡率在 2%至 56%之间,其中一半发生在产后 12 周内。虽然已经确定了 PPCM 的危险因素,但预测 PPCM 患者的心脏性猝死仍然很困难。本研究描述了接受植入式心律转复除颤器(ICD)的 PPCM 患者和对照患者的特征和结局。

方法和结果

使用 2003 年至 2009 年期间的 ICD 医疗医嘱和死亡索引搜索来描述患有 PPCM(n=107)或匹配的非妊娠、非缺血性扩张型心肌病(NIDCM;n=159)的女性(年龄 17-43 岁)的特征。两组患者的人口统计学特征相似。PPCM 患者的 ICD 使用平均为 124±123 天,NIDCM 患者为 96±83 天。没有 PPCM 患者因室性心动过速/心室颤动接受过合适的电击治疗;1 例 NIDCM 患者接受了 2 次成功的电击治疗。在 ICD 使用期间,没有 PPCM 患者死亡,而同期有 11 例 NIDCM 患者死亡。在 ICD 使用后,分别有 3 例 PPCM 和 13 例 NIDCM 患者死亡。

结论

与已发表的数据相比,PPCM 患者的死亡率为 2.8%(3.0±1.2 年),相对较低。PPCM 患者的 ICD 治疗作用值得进一步研究。

相似文献

1
Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator.使用可穿戴心脏除颤器的女性围产期与非围产期心肌病的特征和结局。
J Card Fail. 2012 Jan;18(1):21-7. doi: 10.1016/j.cardfail.2011.09.004. Epub 2011 Oct 19.
2
Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.围生期心肌病伴严重左心室功能障碍患者发生心室颤动的风险-可穿戴式除颤器的价值。
Eur J Heart Fail. 2014 Dec;16(12):1331-6. doi: 10.1002/ejhf.188. Epub 2014 Nov 5.
3
Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use.围生期心肌病:恢复的预测因素和植入式心脏复律除颤器的使用现状。
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2831-9. doi: 10.1016/j.jacc.2014.04.014. Epub 2014 May 7.
4
Use of the wearable external cardiac defibrillator in children.可穿戴式体外心脏除颤器在儿童中的应用。
Pacing Clin Electrophysiol. 2010 Jun 1;33(6):742-6. doi: 10.1111/j.1540-8159.2010.02702.x. Epub 2010 Feb 23.
5
Understanding Peripartum Cardiomyopathy.了解围产期心肌病。
Annu Rev Med. 2018 Jan 29;69:165-176. doi: 10.1146/annurev-med-041316-090545. Epub 2017 Aug 16.
6
Utility of the Wearable Cardioverter-Defibrillator in Patients With Newly Diagnosed Cardiomyopathy: A Decade-Long Single-Center Experience.新式心肌病患者佩戴式除颤器的实用性:长达十年的单中心经验。
J Am Coll Cardiol. 2015 Dec 15;66(23):2607-2613. doi: 10.1016/j.jacc.2015.09.079.
7
National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy.心肌病患者长期使用可穿戴式心脏复律除颤器的国家经验。
J Interv Card Electrophysiol. 2017 Jan;48(1):11-19. doi: 10.1007/s10840-016-0194-6. Epub 2016 Oct 17.
8
Wearable defibrillator in congenital structural heart disease and inherited arrhythmias.可穿戴除颤器在先天性结构性心脏病和遗传性心律失常中的应用。
Am J Cardiol. 2011 Dec 1;108(11):1632-8. doi: 10.1016/j.amjcard.2011.07.021. Epub 2011 Sep 3.
9
Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.可穿戴式心脏除颤器作为心脏移植的桥梁:国家数据库分析。
J Heart Lung Transplant. 2015 Oct;34(10):1305-9. doi: 10.1016/j.healun.2015.04.004. Epub 2015 May 4.
10
EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM.EURObservational Research Programme:一项关于围产期心肌病(PPCM)的全球性注册研究,与欧洲心脏病学会心力衰竭协会的 PPCM 工作组合作。
Eur J Heart Fail. 2014 May;16(5):583-91. doi: 10.1002/ejhf.68. Epub 2014 Mar 3.

引用本文的文献

1
Efficacy and Safety of Implantable Cardioverter-Defibrillator Use in Peripartum Cardiomyopathy.植入式心脏复律除颤器在围产期心肌病中的疗效与安全性
JACC Adv. 2025 May 30;4(6 Pt 1):101827. doi: 10.1016/j.jacadv.2025.101827.
2
Hypertensive Disorders of Pregnancy and Peripartum Cardiomyopathy: A Meta-Analysis of Prevalence and Impact on Left Ventricular Function and Mortality.妊娠期高血压疾病与围产期心肌病:患病率及对左心室功能和死亡率影响的荟萃分析
J Clin Med. 2025 Mar 4;14(5):1721. doi: 10.3390/jcm14051721.
3
Maternal heart failure: state-of-the-art review.
孕产妇心力衰竭:最新综述
Heart Fail Rev. 2025 Mar;30(2):337-351. doi: 10.1007/s10741-024-10466-y. Epub 2024 Nov 12.
4
Wearable cardioverter defibrillator for preventing sudden cardiac death in patients at risk: An updated systematic review of comparative effectiveness and safety.用于预防高危患者心源性猝死的可穿戴式心脏复律除颤器:比较有效性和安全性的最新系统评价
Int J Cardiol Heart Vasc. 2023 Mar 28;45:101189. doi: 10.1016/j.ijcha.2023.101189. eCollection 2023 Apr.
5
Usage of the wearable cardioverter-defibrillator during pregnancy.孕期可穿戴式心脏复律除颤器的使用。
Int J Cardiol Heart Vasc. 2022 Jun 3;41:101066. doi: 10.1016/j.ijcha.2022.101066. eCollection 2022 Aug.
6
Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.新发心力衰竭患者左心室功能的延迟改善取决于病因——PROLONG-II 亚研究。
Sensors (Basel). 2022 Mar 5;22(5):2037. doi: 10.3390/s22052037.
7
A wearable cardioverter defibrillator with a low false alarm rate.一款具有低误报率的可穿戴式心脏除颤器。
J Cardiovasc Electrophysiol. 2022 May;33(5):831-842. doi: 10.1111/jce.15417. Epub 2022 Feb 28.
8
Multiparameter Monitoring with a Wearable Cardioverter Defibrillator.可穿戴式除颤器的多参数监测。
Sensors (Basel). 2021 Dec 21;22(1):22. doi: 10.3390/s22010022.
9
Heart failure in pregnancy: what is the long-term impact of pregnancy on cardiac function? A tertiary care centre experience and systematic review.妊娠合并心力衰竭:妊娠对心功能的长期影响是什么?一家三级保健中心的经验和系统评价。
Open Heart. 2021 Aug;8(2). doi: 10.1136/openhrt-2021-001587.
10
Management of Implantable Cardioverter-Defibrillators during Pregnancy-A Systematic Review.孕期植入式心脏复律除颤器的管理——一项系统评价
J Clin Med. 2021 Apr 14;10(8):1675. doi: 10.3390/jcm10081675.